Understanding existing antipsychotics and newer drug targets in schizophrenia

A. Avinash, Sushil Kiran Kunder, Anurag Pathak, Navin Patil, Veena Nayak

Research output: Contribution to journalArticle

Abstract

Schizophrenia is a chronic, debilitating, prototypic psychotic disorder, which has antipsychotics as the mainstay of treatment. Antipsychotics are broadly divided into two: Typical and atypical. While typical drugs were popular in clinical practice until a few years ago, there are slowly being replaced by the atypical drugs, mainly because of improved efficacy and lesser incidence of extra-pyramidal symptoms. However, the newer drugs have their own demerits, in the form of other adverse effects, like metabolic syndrome, QT prolongation and sudden death. Several newer targets have been identified in the field, which might help in bringing about drugs with improved efficacy and safety parameters.

Original languageEnglish
Pages (from-to)1507-1520
Number of pages14
JournalResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Volume7
Issue number1
Publication statusPublished - 01-01-2016

Fingerprint

Antipsychotic Agents
Schizophrenia
Pharmaceutical Preparations
Sudden Death
Psychotic Disorders
Safety
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{a36ea30531394b26ab84e5f6079a1cfa,
title = "Understanding existing antipsychotics and newer drug targets in schizophrenia",
abstract = "Schizophrenia is a chronic, debilitating, prototypic psychotic disorder, which has antipsychotics as the mainstay of treatment. Antipsychotics are broadly divided into two: Typical and atypical. While typical drugs were popular in clinical practice until a few years ago, there are slowly being replaced by the atypical drugs, mainly because of improved efficacy and lesser incidence of extra-pyramidal symptoms. However, the newer drugs have their own demerits, in the form of other adverse effects, like metabolic syndrome, QT prolongation and sudden death. Several newer targets have been identified in the field, which might help in bringing about drugs with improved efficacy and safety parameters.",
author = "A. Avinash and Kunder, {Sushil Kiran} and Anurag Pathak and Navin Patil and Veena Nayak",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "1507--1520",
journal = "Research Journal of Pharmaceutical, Biological and Chemical Sciences",
issn = "0975-8585",
publisher = "RJPBCS",
number = "1",

}

Understanding existing antipsychotics and newer drug targets in schizophrenia. / Avinash, A.; Kunder, Sushil Kiran; Pathak, Anurag; Patil, Navin; Nayak, Veena.

In: Research Journal of Pharmaceutical, Biological and Chemical Sciences, Vol. 7, No. 1, 01.01.2016, p. 1507-1520.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Understanding existing antipsychotics and newer drug targets in schizophrenia

AU - Avinash, A.

AU - Kunder, Sushil Kiran

AU - Pathak, Anurag

AU - Patil, Navin

AU - Nayak, Veena

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Schizophrenia is a chronic, debilitating, prototypic psychotic disorder, which has antipsychotics as the mainstay of treatment. Antipsychotics are broadly divided into two: Typical and atypical. While typical drugs were popular in clinical practice until a few years ago, there are slowly being replaced by the atypical drugs, mainly because of improved efficacy and lesser incidence of extra-pyramidal symptoms. However, the newer drugs have their own demerits, in the form of other adverse effects, like metabolic syndrome, QT prolongation and sudden death. Several newer targets have been identified in the field, which might help in bringing about drugs with improved efficacy and safety parameters.

AB - Schizophrenia is a chronic, debilitating, prototypic psychotic disorder, which has antipsychotics as the mainstay of treatment. Antipsychotics are broadly divided into two: Typical and atypical. While typical drugs were popular in clinical practice until a few years ago, there are slowly being replaced by the atypical drugs, mainly because of improved efficacy and lesser incidence of extra-pyramidal symptoms. However, the newer drugs have their own demerits, in the form of other adverse effects, like metabolic syndrome, QT prolongation and sudden death. Several newer targets have been identified in the field, which might help in bringing about drugs with improved efficacy and safety parameters.

UR - http://www.scopus.com/inward/record.url?scp=84955304528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955304528&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 1507

EP - 1520

JO - Research Journal of Pharmaceutical, Biological and Chemical Sciences

JF - Research Journal of Pharmaceutical, Biological and Chemical Sciences

SN - 0975-8585

IS - 1

ER -